Welcome to our dedicated page for Traws Pharma news (Ticker: TRAW), a resource for investors and traders seeking the latest updates and insights on Traws Pharma stock.
Traws Pharma, Inc. (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company whose news flow centers on the development of investigational oral antivirals for major respiratory viral threats. Company announcements frequently highlight progress in its COVID-19 and influenza programs, including clinical trial milestones, interim data readouts, regulatory interactions and partnering activities.
A key focus of Traws’ news coverage is ratutrelvir, an investigational oral Mpro (3CL protease) inhibitor designed to treat SARS-CoV-2/COVID-19 without ritonavir. Recent press releases describe Phase 2 studies that compare ratutrelvir with PAXLOVID in patients with mild-to-moderate COVID-19 and evaluate its use in PAXLOVID-ineligible patients who face drug–drug interaction concerns with ritonavir-boosted regimens. Interim analyses reported by the company discuss patient-reported symptom outcomes, safety, tolerability and the presence or absence of viral or symptom rebound, as well as potential implications for Long COVID.
News items also cover tivoxavir marboxil (TXM), an investigational single-dose CAP-dependent endonuclease inhibitor for bird flu and seasonal influenza. Traws’ updates describe Phase 1 findings, preclinical results in multiple animal models using H5N1 virus, and interactions with agencies such as BARDA regarding potential inclusion of TXM in antiviral stockpiling initiatives for pandemic preparedness.
Investors following TRAW news can expect regular disclosures on quarterly financial results, business highlights, intellectual property and asset acquisitions, board and management changes, and corporate governance matters, as reflected in the company’s earnings releases and SEC filings. In addition, third-party announcements from collaborators, such as organizations providing chemistry, manufacturing and controls or AI-enabled predictive pharmacology support for ratutrelvir, may reference Traws’ clinical progress.
This news page aggregates these developments so readers can monitor how Traws’ clinical data, regulatory milestones and strategic decisions evolve over time. For those tracking antiviral pipelines for COVID-19, Long COVID, bird flu and seasonal influenza, the TRAW news feed offers a centralized view of the company’s publicly reported activities.
Traws Pharma (NASDAQ: TRAW), a clinical-stage biopharmaceutical company focused on developing therapies for respiratory viral diseases, will host a conference call and webcast to discuss its Q2 2025 financial results on Thursday, August 14, 2025, at 8:30 AM ET.
The company will provide updates on its financial performance for the quarter ended June 30, 2025, along with recent business developments. Investors can access the call through U.S. (1-877-407-0789) or International (1-201-689-8562) dial-in numbers using Conference ID 13754425. A replay will be available on the company's website.
Traws Pharma (NASDAQ: TRAW) has announced multiple regulatory submissions advancing its antiviral pipeline. The company has submitted a Phase 2 protocol to HREC for tivoxavir marboxil (TXM) to evaluate its effectiveness against both seasonal and bird flu in the Southern Hemisphere. Additionally, briefing documents were submitted to the FDA for a Type D meeting regarding potential accelerated approval of TXM for bird flu treatment.
The company has also submitted a Phase 2 study protocol to HREC for ratutrelvir, their protease inhibitor that doesn't require ritonavir co-administration, to evaluate its effectiveness against COVID-19. This study will compare ratutrelvir to PAXLOVID® in newly diagnosed patients, with specific focus on disease rebound and Long COVID development. The study includes a separate arm for patients ineligible for PAXLOVID® treatment.
The TXM study will be conducted in Australia and Southeast Asian countries with high rates of human bird flu infections, while the ratutrelvir study will evaluate patients on a 10-day treatment regimen compared to PAXLOVID's® 5-day regimen.
Traws Pharma (NASDAQ: TRAW) reported its Q1 2025 financial results and provided updates on its antiviral drug development programs. The company's lead candidate tivoxavir marboxil (TXM) for bird/seasonal flu showed promising results in animal studies, with a FDA briefing document submitted on April 24, 2025. Their second candidate ratutrelvir for COVID treatment is preparing for regulatory briefings.
Financial highlights include: $15.9M in cash and equivalents (vs $21.3M in Q4 2024), revenue of $57K, R&D expenses of $2.5M, and net income of $21.5M ($2.17 per share). The company expects its cash runway to extend into Q1 2026.
Recent management changes include Iain D. Dukes appointment as Interim CEO and Jack Stover as Board Chairman. The company is also seeking partnership opportunities for its legacy oncology assets.
Traws Pharma (NASDAQ: TRAW) reported its full year 2024 financial results and business updates. The company's lead product candidate, tivoxavir marboxil (TXM), showed promising results in bird flu treatment through three animal models and Phase 1 data. The company is pursuing potential accelerated approval via FDA's 'Animal Rule'.
Financial highlights include:
- Cash position of $21.3 million as of December 31, 2024
- R&D expenses increased to $12.8 million from $11.4 million in 2023
- G&A expenses rose to $12.3 million from $9.1 million in 2023
- Net loss of $166.5 million ($35.21 per share) compared to $18.9 million in 2023
The company completed a $20 million financing in December 2024 and expects its cash runway to extend into Q1 2026. CEO Werner Cautreels will retire effective March 31, 2025, with Chairman Iain D. Dukes assuming the role of Interim CEO.
Traws Pharma (NASDAQ: TRAW) announced key management changes as CEO Werner Cautreels, PhD, will retire effective March 31, 2025, following the company's Annual Report filing. Executive Board Chairman Iain D. Dukes, D Phil, will step in as Interim CEO while maintaining his Chairman position.
Dr. Cautreels will remain on the Board of Directors and transition to a consulting role as special advisor for the next year. Under his leadership, the company completed the merger with Trawsfynydd to form Traws Pharma, advancing two clinical-stage antiviral candidates for bird flu and COVID.
The company will hold an Investor Update call on March 31, 2025, at 10:00 AM ET to review pipeline progress. Traws Pharma focuses on developing novel therapies targeting respiratory viral diseases through oral small molecule antivirals.
Traws Pharma (NASDAQ: TRAW) has announced a virtual investor event scheduled for March 31, 2025, at 10:00 AM ET to discuss their key product candidates. The event will feature presentations from former CDC Director Dr. Robert R. Redfield, now Traws' Chief Medical Officer, and Chief Science Officer Dr. C. David Pauza.
The focus will be on two main drug candidates:
- Tivoxavir Marboxil: A single-dose, CAP-dependent endonuclease inhibitor targeting Bird Flu (H5N1)
- Ratutrelvir: A main protease inhibitor for COVID-19, designed to be used without ritonavir
The presentation will cover preclinical proof-of-concept and Phase 1 study data recently presented at ICAR 2025, the public health implications of H5N1 bird flu, and strategies to address COVID-19 clinical rebound and long COVID risks. The event will conclude with a Q&A session.
Traws Pharma (NASDAQ: TRAW) presented positive data for its COVID-19 treatment candidate ratutrelvir at ICAR 2025 in Las Vegas. The drug, designed as a main protease inhibitor, shows promising advantages over current treatments:
Key findings from preclinical and Phase 1 data indicate that ratutrelvir:
- Can be used without ritonavir (a boosting agent), reducing drug interaction risks
- Effectively suppresses 18 different SARS-CoV-2 strains, including nirmatrelvir-resistant and Omicron variants
- Maintains blood levels within therapeutic window at 600 mg/day for 10 days
- Shows excellent safety and tolerability in Phase 1 trials
- Maintains drug levels above EC90 for 2 days after treatment ends
The company is preparing for FDA interactions and Phase 2 studies, with an upcoming Investor Event scheduled for March 31, 2025.
Traws Pharma (NASDAQ: TRAW) announced positive topline results for their antiviral bird flu treatment, tivoxavir marboxil (TXM), in non-human primates. The study demonstrated that a single dose of TXM significantly reduced lung viremia and prevented weight loss in H5N1 bird flu models.
Key findings include:
- TXM-treated animals showed lung virus levels below 2X103 infectious particles/ml, compared to control group levels of up to 1X107
- Control group lost 4.2% body weight over 10 days, while TXM-treated subjects maintained or gained weight
- Results consistent with previous positive outcomes in ferret and mice studies
The company plans to meet with FDA in H1 2025 to discuss potential accelerated approval through the 'Animal Rule' pathway, supported by safety data from Phase I studies in healthy volunteers completed in January 2025. An Investor Event is scheduled for March 31, 2025, to present TXM data and outline next steps.
FAQ
What is the current stock price of Traws Pharma (TRAW)?
What is the market cap of Traws Pharma (TRAW)?
